The Board of Directors of Elan Corporation Plc has formally rejected an unsolicited takeover bid from the US investment group, Royalty Pharma, saying it substantially undervalues the company. This follows a low turnout in a share buyback. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
